Centre may seek legal view on licensing of sterile drugs

The government is actively exploring a proposal to expand central licensing authority over all sterile drug products following a recent Supreme Court decision that restricted the enforcement authority of central officials. A meeting of the drugs consultative committee underscored the essential requirement for specialized regulatory oversight for these sensitive products, aiming for uniform regulations. A dedicated sub-committee will evaluate the proposal's feasibility and gather legal insights before any definitive actions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p6l2iYZ
via IFTTT

Read More

Ayush services sector supports 1.76 million livelihoods; women constitute 43% of the workforce

The Ayush services sector supports 1.76 million livelihoods in India and has a significant female workforce. Women's participation in organized segments, including hospitals, exceeds 50 percent in several areas. The sector has the potential to expand substantially, generating an estimated USD 216-318 billion by 2047. Ayurveda remains the largest individual system of revenue generation within the sector, contributing significantly.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zRjr0f8
via IFTTT

Read More

Wall Street’s $10 billion India hospital bet sparks a fight over bills

Wall Street has poured about $10 billion into Indian hospital chains over the past five years, with investors including Blackstone, KKR, TPG and General Atlantic betting on India’s huge shortage of hospital beds and rising demand for specialised care.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W2kVamB
via IFTTT

Read More

Robotic surgery gains rapid ground in India, Delhi NCR leads: Experts

India is rapidly scaling up robotic surgery, with procedures rising from 8,912 in 2021 to 44,857 in 2025, while Delhi NCR has emerged as the country’s biggest hub with 39 hospitals using robotic systems. Experts say the next phase could include wider use of telesurgery, remote mentoring and access to specialist care beyond major cities, subject to regulatory and cybersecurity safeguards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EZDxXmd
via IFTTT

Read More

Maharashtra FDA cancels Cipla's Pune warehouse licences over Reactin Plus packaging claims

Maharashtra's Food and Drug Administration has cancelled Cipla Pharma's distribution licenses due to serious violations. The FDA discovered irregularities with Reactin Plus Tablets, including misbranding and unsafe storage practices. Following inspections, it was revealed that expired medicines were stored incorrectly without proper documentation. The licensing authority’s decision was based on findings from earlier proceedings and legal directions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lwzvNLP
via IFTTT

Read More

India has biotech talent and know-how, but funding ecosystem lags: Lilly CEO

Eli Lilly intends to innovate in the weight-loss market, launching up to four new products in the coming years. The success of Mounjaro and Zepbound significantly boosted the company's sales and market value. Eli Lilly sees potential in India's biotech sector, despite challenges in the research funding environment. The company is open to partnerships with Indian biotechnology firms for future collaborations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/v7L6naV
via IFTTT

Read More

‘India’s biotech ecosystem holds tremendous promise’: Eli Lilly CEO

Eli Lilly has experienced significant growth, reaching a market capitalization over $1 trillion. The company aims to maintain its leadership in anti-obesity drugs through ongoing innovation and development. With successful trials for drugs like retatrutide and Foundayo, Lilly is expanding its product offerings. The company recognizes the importance of India as a growing market for healthcare investments and partnerships.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/s7BoJzj
via IFTTT

Read More